The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

• Main Authors: Gabriella Giancane (Author), Claudio Lavarello (Author), Angela Pistorio (Author), Sheila K. Oliveira (Author), Francesco Zulian (Author), Ruben Cuttica (Author), Michel Fischbach (Author), Bo Magnusson (Author), Serena Pastore (Author), Roberto Marini (Author), Silvana Martino (Author), Anne Pagnier (Author), Christine Soler (Author), Valda Staņēvicha (Author), Rebecca Ten Cate (Author), Yosef Uziel (Author), Jelena Vojinovic (Author), Elena Fueri (Author), Angelo Ravelli (Author), Alberto Martini (Author), Nicolino Ruperto (Author), for the Paediatric Rheumatology International Trials Organisation (PRINTO) (Author)
• Format: Book
• Published: BMC, 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM patients. No clear evidence based guidelines are actually...